Exelixis files second patent infringement suit against Teva over generic CABOMETYX

EXELIXIS, INC.

Exelixis filed complaint against Teva for infringing U.S. Patent No. 11,298,349 covering CABOMETYX (cabozantinib) tablets.
Teva filed ANDA with Paragraph IV certification; Exelixis seeks injunction and FDA approval delay until patent expires Feb 10, 2032.
This is the second case; first case (2021) is stayed administratively, asserting three other patents expiring July 9, 2033.
No trial scheduled yet; Exelixis seeks equitable relief to block Teva's generic launch before patent expiration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.